However, AbbVie's dividend yield today hovers around 2.6% -- the lowest level since early 2018. For investors accustomed to ...
Humira, the drug that built AbbVie (NYSE:ABBV), sold $756 million last quarter, down 35.9%. And yet total revenue still ...
US FDA approves additional US manufacturing capacity for Simlandi, Alvotech’s biosimilar to Humira: Reykjavik, Iceland Tuesday, October 6, 2026, 17:00 Hrs [IST] Alvotech, a glob ...
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and ...
The target change followed a strong second-quarter operating picture. AbbVie reported USD 16.99 billion in revenue for Q2 ...
Key TakeawaysAlvotech shares rose 13% after the FDA approved a second Reykjavik production suite for Simlandi, its Humira biosimilar, doubling the capacity available for U. S.
The approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of the company’s two ...
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites Further confirms resolution of FDA inspection-related ...
6d
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik ...
Alvotech ( ) has provided an update. On October 5, 2026, Alvotech reported that the U.S. Food and Drug Administration approved additional manufacturing capacity at its Reykjavik f ...
An Illinois federal judge tossed all but one claim in a sheet metal worker health plan's putative class action against AbbVie for allegedly causing artificially inflated prices for the rheumatoid ...
Yusimry is indicated to treat a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results